After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
SOURCE Faruqi & Faruqi, LLP
These names frequently trade at low multiples to current assets and may (but may not) be worthy of purchase.
Just five non-biotech names trade below net current asset value.
Searching for value plays produces few options, right now.
But sometimes it just takes patience, and a bit of work, to make them smell sweet.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.